HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy.

Abstract
Globoid cell leukodystrophy (GLD) is a lysosomal storage disease caused by deficient activity of β-galactocerebrosidase (GALC). The infantile forms manifest with rapid and progressive central and peripheral demyelination, which represent a major hurdle for any treatment approach. We demonstrate here that neonatal lentiviral vector-mediated intracerebral gene therapy (IC GT) or transplantation of GALC-overexpressing neural stem cells (NSC) synergize with bone marrow transplant (BMT) providing dramatic extension of lifespan and global clinical-pathological rescue in a relevant GLD murine model. We show that timely and long-lasting delivery of functional GALC in affected tissues ensured by the exclusive complementary mode of action of the treatments underlies the outstanding benefit. In particular, the contribution of neural stem cell transplantation and IC GT during the early asymptomatic stage of the disease is instrumental to enhance long-term advantage upon BMT. We clarify the input of central nervous system, peripheral nervous system and periphery to the disease, and the relative contribution of treatments to the final therapeutic outcome, with important implications for treatment strategies to be tried in human patients. This study gives proof-of-concept of efficacy, tolerability and clinical relevance of the combined gene/cell therapies proposed here, which may constitute a feasible and effective therapeutic opportunity for children affected by GLD.
AuthorsAlessandra Ricca, Nicole Rufo, Silvia Ungari, Francesco Morena, Sabata Martino, Wilem Kulik, Valeria Alberizzi, Alessandra Bolino, Francesca Bianchi, Ubaldo Del Carro, Alessandra Biffi, Angela Gritti
JournalHuman molecular genetics (Hum Mol Genet) Vol. 24 Issue 12 Pg. 3372-89 (Jun 15 2015) ISSN: 1460-2083 [Electronic] England
PMID25749991 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author 2015. Published by Oxford University Press.
Chemical References
  • Galactosylceramidase
Topics
  • Animals
  • Apoptosis (genetics)
  • Axons (metabolism, pathology)
  • Bone Marrow Transplantation
  • Brain (metabolism)
  • Cell Differentiation
  • Cell- and Tissue-Based Therapy
  • Central Nervous System (metabolism, physiopathology)
  • Disease Models, Animal
  • Enzyme Activation
  • Galactosylceramidase (genetics, metabolism)
  • Genetic Therapy
  • Gliosis (genetics, metabolism, pathology)
  • Graft Survival
  • Humans
  • Leukodystrophy, Globoid Cell (diagnosis, genetics, metabolism, mortality, therapy)
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Myelin Sheath (metabolism)
  • Neural Stem Cells (cytology, metabolism)
  • Peripheral Nervous System (metabolism, physiopathology)
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: